<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00456794</url>
  </required_header>
  <id_info>
    <org_study_id>6002-US-006</org_study_id>
    <nct_id>NCT00456794</nct_id>
  </id_info>
  <brief_title>12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa</brief_title>
  <official_title>A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study of the Efficacy of Doses of 20 and 60 mg/Day Istradefylline as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Kirin Pharmaceutical Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Kirin Pharmaceutical Development, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 12-week, multicenter, double-blind, randomized study designed to evaluate the safety and
      efficacy of 20 and 60 mg/day istradefylline compared with placebo in subjects with OFF-time
      phenomena and advanced Parkinson's disease treated with levodopa/carbidopa.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <completion_date type="Actual">October 2003</completion_date>
  <primary_completion_date type="Actual">October 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline to Endpoint in percentage of awake time per day in an OFF state based on the subjects' valid ON/OFF Parkinson's disease diary data.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Actual values and mean change from Baseline in percentage and total hours of awake time per day in the OFF state and ON state, UPDRS I-IV, II and III Scores during ON and OFF states, Global Clinical Impression-Improvement (CGI-I), safety</measure>
  </secondary_outcome>
  <enrollment>325</enrollment>
  <condition>Parkinson's Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Istradefylline (KW-6002)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. United Kingdom Parkinson's Disease Society brain bank diagnostic criteria (Steps 1 and
             2).

          2. Modified Hoehn and Yahr in the OFF state of II-IV.

          3. Treated with levodopa/carbidopa for at least one year with a stable regimen for 4
             weeks prior to randomization.

          4. Taking at least 4 doses of levodopa/carbidopa per day (3 doses if at least 2 doses
             contained slow-release formulation) with predictable end of dose wearing off.

          5. Successfully competed Parkinson's disease patient diary training with at least 120
             minutes of OFF time per day.

          6. Stable regimen of other antiparkinson's medications for 4 weeks prior to
             randomization.

          7. At least 30 years of age and able to give written informed consent.

        Exclusion Criteria:

          1. Treatment with liquid levodopa/carbidopa within 4 weeks of randomization.

          2. Treatment with MAO inhibitors except selegiline.

          3. Treatment within 3 months with centrally acting dopamine antagonists (6 months for
             depot formulations), e.g., antipsychotic neuroleptics, metoclopramide, buspirone,
             amoxapine.

          4. Neurosurgical operation for Parkinson's disease.

          5. Atypical parkinsonism or secondary parkinsonism variants.

          6. Diagnosis of cancer or evidence of continued disease within 5 years.

          7. Clinically significant illness of any organ system (e.g., ALT or AST &gt; 1.5 times the
             upper limit of normal).

          8. Mini-Mental Status Examination score of 25 or less.

          9. History of drug or alcohol abuse or dependence within 2 years.

         10. History of psychotic illness or seizures.

         11. Clinically relevant depression disorder.

         12. History of neuroleptic malignant syndrome.

         13. Pregnancy or lactation. Women of child bearing potential must use a reliable method of
             contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil Sussman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Kyowa Kirin Pharmaceutical Development, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Contact Kyowa Pharmaceutical, Inc.</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2007</study_first_submitted>
  <study_first_submitted_qc>April 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2007</study_first_posted>
  <last_update_submitted>July 13, 2016</last_update_submitted>
  <last_update_submitted_qc>July 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2016</last_update_posted>
  <keyword>Parkinson's disease</keyword>
  <keyword>Levodopa</keyword>
  <keyword>End of dose wearing off</keyword>
  <keyword>OFF time</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Istradefylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

